With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 23, 2017. A large phase 3 trial published this week in JAMA shows no difference in median survival with the use of cetuximab (30 months) vs bevacizumab (29 months) in combo with chemo for advanced and/or metastatic KRAS wt colorectal cancer. 1137 patients previously untreated for advanced or metastatic disease were randomized to upfront cetuximab (anti-EGFR) or bevacizumab (anti-VEGF) in combo with physician’s choice of 5FU-based chemo with mFOLFOX6 (includes oxaliplatin) or FOLOFIRI (includes irinotecan). So what’s the take-away? Interestingly, both groups did considerably better than the predicted median overall survival of 22 months used for the power analysis. Possible explanations include the increased utilization of tumor-directed therapies in oligometastatic disease as well as exclusion of KRAS mutant patients. In this contest, both sides win.